Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study

August 5, 2016 12:42 PM

22 0

Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study

Shares of Bristol-Myers plunge; competitor Merck’s stock rises sharply

Bristol-Myers Squibb Co. said a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint.

Read more

To category page

Loading...